Literature DB >> 22222213

Reaction of complement factors varies with prion strains in vitro and in vivo.

Rie Hasebe1, Gregory J Raymond, Motohiro Horiuchi, Byron Caughey.   

Abstract

Roles of complement factors in prion infection of the central nervous system remain unclear. In this study, we assessed the strain-dependent reactivity of complement factors in prion infections of Neuro2a (N2a) cells and mouse brains. N2a cells persistently infected with either Chandler or 22L scrapie strains were cultured in the presence of normal mouse serum (NMS), followed by staining with phosphatidylserine binding protein and early apoptosis marker Annexin V. The proportion of Annexin V positive cells was increased both in Chandler- and 22L-infected cells. Preincubation of NMS with anti-C1q, C3 and/or C9 antibodies reduced Annexin V positive cells in Chandler-infected cells, while only anti-C3 antibodies were effective on 22L-infected cells. The immunohistochemistry showed that deposition of C1q and C3 was different between Chandler- and 22L-infected mouse brains. These results indicate that the reactivity of complement factors differs between prion strains both in vitro and in vivo.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222213      PMCID: PMC3275752          DOI: 10.1016/j.virol.2011.11.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  48 in total

1.  Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis.

Authors:  S M Dashiell; H Rus; C L Koski
Journal:  Glia       Date:  2000-04       Impact factor: 7.452

2.  Complement activation in human prion disease.

Authors:  Gabor G Kovacs; Philippe Gasque; Thomas Ströbel; Elisabeth Lindeck-Pozza; Michaela Strohschneider; James W Ironside; Herbert Budka; Marin Guentchev
Journal:  Neurobiol Dis       Date:  2004-02       Impact factor: 5.996

3.  C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis.

Authors:  J Hughes; M Nangaku; C E Alpers; S J Shankland; W G Couser; R J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2000-05

4.  C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway.

Authors:  L Soane; H J Cho; F Niculescu; H Rus; M L Shin
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

5.  Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity.

Authors:  M Sárvári; I Vágó; C S Wéber; J Nagy; P Gál; M Mák; J P Kósa; P Závodszky; T Pázmány
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

6.  Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie.

Authors:  N A Mabbott; M E Bruce; M Botto; M J Walport; M B Pepys
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

7.  Complement facilitates early prion pathogenesis.

Authors:  M A Klein; P S Kaeser; P Schwarz; H Weyd; I Xenarios; R M Zinkernagel; M C Carroll; J S Verbeek; M Botto; M J Walport; H Molina; U Kalinke; H Acha-Orbea; A Aguzzi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

8.  New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products.

Authors:  David A Kocisko; Gerald S Baron; Richard Rubenstein; Jiancao Chen; Salomon Kuizon; Byron Caughey
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Cutting edge: proliferating fibroblasts respond to collagenous C1q with phosphorylation of p38 mitogen-activated protein kinase and apoptotic features.

Authors:  Sandra Bordin; Douglas Whitfield
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

10.  The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease.

Authors:  T Ishii; S Haga; S Yagishita; J Tateishi
Journal:  Appl Pathol       Date:  1984
View more
  6 in total

1.  Genetic depletion of complement receptors CD21/35 prevents terminal prion disease in a mouse model of chronic wasting disease.

Authors:  Brady Michel; Adam Ferguson; Theodore Johnson; Heather Bender; Crystal Meyerett-Reid; Bruce Pulford; Adriana von Teichman; Davis Seelig; John H Weis; Glenn C Telling; Adriano Aguzzi; Mark D Zabel
Journal:  J Immunol       Date:  2012-09-21       Impact factor: 5.422

2.  Complement protein C3 exacerbates prion disease in a mouse model of chronic wasting disease.

Authors:  Brady Michel; Adam Ferguson; Theodore Johnson; Heather Bender; Crystal Meyerett-Reid; A Christy Wyckoff; Bruce Pulford; Glenn C Telling; Mark D Zabel
Journal:  Int Immunol       Date:  2013-09-13       Impact factor: 4.823

Review 3.  The Good, the Bad, and the Ugly of Dendritic Cells during Prion Disease.

Authors:  Neil Andrew Mabbott; Barry Matthew Bradford
Journal:  J Immunol Res       Date:  2015-11-30       Impact factor: 4.818

4.  Low activity of complement in the cerebrospinal fluid of the patients with various prion diseases.

Authors:  Cao Chen; Yan Lv; Qi Shi; Wei Zhou; Kang Xiao; Jing Sun; Xiao-Dong Yang; Xiao-Ping Dong
Journal:  Infect Dis Poverty       Date:  2016-05-03       Impact factor: 4.520

Review 5.  Prion disease and the innate immune system.

Authors:  Barry M Bradford; Neil A Mabbott
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

6.  Ablation of CCAAT/Enhancer-Binding Protein Delta (C/EBPD): Increased Plaque Burden in a Murine Alzheimer's Disease Model.

Authors:  Manuel Lutzenberger; Michael Burwinkel; Constanze Riemer; Victoria Bode; Michael Baier
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.